Impact of lumacaf tor/ivacaf tor and tezacaf tor/ivacaf tor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis

McElvaney, OJ; Heltshe, SL; Odem-Davis, K; West, NE; Sanders, DB; Fogarty, B; VanDevanter, DR; Flume, PA; Goss, CH

Goss, CH (通讯作者),Univ Washington, Med Ctr, Campus Box 356522,1959 Northeast Pacific St, Seattle, WA 98195 USA.

JOURNAL OF CYSTIC FIBROSIS, 2023; 22 (5): 875

Abstract

Background: Pulmonary exacerbations (PEx) remain a major cause of morbidity and mortality in people with cystic fibrosis (PWCF). Although the combinat......

Full Text Link